Atlas Trials

TRT for ES-SCLC After First Line Treatment With Immune Checkpoint Inhibitors

Clinical trial NCT05544149 · UNKNOWN

Trial details

NCT number
NCT05544149
Sponsor
Zhejiang Cancer Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
SCLC,Extensive Stage
Start date
2022-09-01
Primary completion
2024-08-30
Enrollment
42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.